Immunovant Inc
IMVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.93B
Close$
$4.94
87.4% downside
Current Fair Value
87.4% downsideOvervalued by 87.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.93 Billion |
|---|---|
| Enterprise Value | $7.03 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.77 |
| Outstanding Shares | 203,709,320 |
Return
| Return on Equity | -59.30% |
|---|---|
| Return on Assets | -52.83% |
| Return on Invested Capital | -48.21% |
Valuation & Multiples
| P/E Ratio | -13.89 |
|---|---|
| PEG | -35.71 |
| Price to Sales | - |
| Price to Book Ratio | 9.84 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -17.1 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 4, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.63
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 10.46% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.97%▼ 59.65% |
|---|---|
| Total Invested | $76.20M▼ 97.23% |
| Investors Holding | 37▼ 189.00% |
ESG Score
No data